You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 7, 2024

Details for Patent: 10,842,751

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 10,842,751 protect, and when does it expire?

Patent 10,842,751 protects DELSTRIGO and is included in one NDA.

This patent has twenty-three patent family members in twenty countries.

Summary for Patent: 10,842,751

Title:	Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine
Abstract:	The instant invention relates to pharmaceutical compositions comprising doravirine, tenofovir disoproxil fumarate and lamivudine. These compositions are useful for the treatment of HIV infection. Also disclosed are processes for making said pharmaceutical compositions.
Inventor(s):	Panmai; Santipharp (Cranford, NJ), Tatavarti; Aditya (Chalfont, PA), Farrington; Andrew M. (Collegeville, PA), Biyyala; Varsha (Somerset, NJ), Allain; Leonardo R. (Lansdale, PA), Nefliu; Marcela (Schwenksville, PA), Klinzing; Gerard R. (Wilmington, DE), Ren; Jie (Chalfont, PA), Lamm; Matthew (Morristown, NJ)
Assignee:	MERCK SHARP & DOHME CORP. (Rahway, NJ)
Application Number:	16/791,398
Patent Claim Types: see list of patent claims	Formulation; Dosage form;

Drugs Protected by US Patent 10,842,751

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Msd Merck Co	DELSTRIGO	doravirine; lamivudine; tenofovir disoproxil fumarate	TABLET;ORAL	210807-001	Aug 30, 2018		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 10,842,751

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2016361612	⤷ Sign Up
Brazil	112018011085	⤷ Sign Up
Canada	3006192	⤷ Sign Up
China	108367008	⤷ Sign Up
Cyprus	1124748	⤷ Sign Up
Denmark	3383397	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.